CCL2 and Friedreich ataxia: MHY5396 treatment significantly reduced the expression of inflammation‐related genes (Ccl2, Ccl5, and Cxcl1) and macrophage markers (Emr1 and Cd163) compared with the FA group (Figure 7A,B).